Los fundamentos de la empresa son relativamente débil. Su valoración está considerada valorada de forma justa,y su reconocimiento institucional es muy alto. Pese a que su rendimiento bursátil es débil, la empresa muestra unos fundamentos sólidos. Las acciones se mantienen sin una tendencia clara entre los niveles de soporte y resistencia, así que son adecuadas para el swing trading en un mercado lateral.
Puntuación de Trinity Biotech PLC
Información Relacionada
Ranking de la industria
158 / 210
Clasificación general
458 / 4616
Industria
Equipamiento y suministros sanitarios
Resistencia y Soporte
Sin datos
Gráfico de radar
Precio actual
Anterior
Objetivo de los analistas
Basado en un total de
0
analistas
--
Calificación actual
--
Precio objetivo
--
Espacio en ascenso
Descargo de responsabilidad: Las calificaciones de los analistas y los precios objetivo son proporcionados por LSEG con fines informativos únicamente y no constituyen asesoramiento de inversión.
Aspectos destacados de Trinity Biotech PLC
Puntos fuertesRiesgo
Trinity Biotech plc is an Ireland-based commercial stage biotechnology company. The Company is focused on human diagnostics and diabetes management solutions, including wearable biosensors. The Company develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market and has also entered the wearable biosensor industry. It intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. Its products are used to detect infectious diseases and to quantify the level of Hemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. The Company, through EpiCapture Limited, is also developing a non-invasive test for monitoring the risk of aggressive prostate cancer. The Company sells its products direct in the United States and through a network of international distributors.
Creciendo
La empresa se encuentra en una fase de crecimiento. Sus ingresos anuales más recientes ascienden a 61.55M USD.
Valorada de forma justa
El PE más reciente de la empresa es -0.19, en un rango percentil medio de 3 años.
Compra institucional
Las tenencias institucionales más recientes son 969.66K acciones, lo que supone un aumento del 42.50% con respecto al trimestre anterior.
Trinity Biotech plc is an Ireland-based commercial stage biotechnology company. The Company is focused on human diagnostics and diabetes management solutions, including wearable biosensors. The Company develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market and has also entered the wearable biosensor industry. It intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. Its products are used to detect infectious diseases and to quantify the level of Hemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. The Company, through EpiCapture Limited, is also developing a non-invasive test for monitoring the risk of aggressive prostate cancer. The Company sells its products direct in the United States and through a network of international distributors.